| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
11,462 |
9,770 |
$873K |
| 99199 |
Unlisted special service, procedure or report |
109,360 |
52,509 |
$541K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
8,492 |
7,192 |
$442K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
4,761 |
4,151 |
$85K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
964 |
794 |
$83K |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
2,536 |
2,174 |
$80K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
973 |
828 |
$73K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
878 |
767 |
$72K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
542 |
459 |
$40K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
2,528 |
2,203 |
$26K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
349 |
290 |
$25K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
856 |
638 |
$23K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
654 |
572 |
$15K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
347 |
300 |
$15K |
| 96127 |
|
2,898 |
2,532 |
$11K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
1,532 |
1,297 |
$11K |
| 96160 |
|
3,340 |
2,862 |
$10K |
| 92551 |
|
4,936 |
4,253 |
$5K |
| 81002 |
|
5,092 |
4,393 |
$5K |
| 36415 |
Collection of venous blood by venipuncture |
1,431 |
1,193 |
$3K |
| 99173 |
|
5,266 |
4,548 |
$2K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
129 |
104 |
$2K |
| 90474 |
|
107 |
98 |
$2K |
| D0145 |
Oral evaluation for a patient under three years of age |
55 |
50 |
$2K |
| 80061 |
Lipid panel |
118 |
85 |
$1K |
| 81003 |
|
640 |
554 |
$1K |
| 90651 |
|
75 |
67 |
$1K |
| 90473 |
|
88 |
84 |
$1K |
| 90461 |
|
167 |
124 |
$855.12 |
| 90686 |
|
1,300 |
1,152 |
$844.05 |
| D1206 |
Topical application of fluoride varnish |
58 |
51 |
$771.41 |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
49 |
37 |
$633.42 |
| 85018 |
|
622 |
514 |
$560.12 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
49 |
44 |
$509.00 |
| 69210 |
|
14 |
12 |
$431.04 |
| 90734 |
|
17 |
14 |
$401.70 |
| 85013 |
|
25 |
25 |
$73.00 |
| 90672 |
|
132 |
118 |
$23.64 |
| 94760 |
|
491 |
449 |
$12.42 |
| 36416 |
|
159 |
140 |
$0.00 |
| 3074F |
|
1,069 |
849 |
$0.00 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
52 |
44 |
$0.00 |
| 3008F |
|
1,106 |
879 |
$0.00 |
| 2001F |
|
1,628 |
1,292 |
$0.00 |
| 90697 |
|
12 |
12 |
$0.00 |
| 90647 |
|
20 |
18 |
$0.00 |
| 90680 |
|
13 |
12 |
$0.00 |
| 90656 |
|
13 |
12 |
$0.00 |
| 3078F |
|
1,043 |
838 |
$0.00 |
| 1160F |
|
4,454 |
3,363 |
$0.00 |
| G9920 |
Screening performed and negative |
1,073 |
848 |
$0.00 |
| 90710 |
|
13 |
12 |
$0.00 |
| 90670 |
|
140 |
117 |
$0.00 |
| 90658 |
|
32 |
28 |
$0.00 |
| 90633 |
|
12 |
12 |
$0.00 |
| 90671 |
|
28 |
24 |
$0.00 |